Patrick de Marco, MD
Allergy · Orange Park, FLNPI 1578598967
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by AstraZeneca at 54.7% of the total. Reporting peaked in 2019 at $7,297 and has fallen 67.1% since, to $2,399 in 2025. Among allergy clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 598 payments — averaging $38.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$13K
- Regeneron Healthcare Solutions, Inc.$2K
- CSL Behring$1K
- GSK$1K
- Novartis$978
- Takeda Pharmaceuticals U.S.A., Inc.$675
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$9,67542%
- Travel & lodging$100%
- Food & beverage$13,21957%
- Education$1501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 120 | $12,609 |
| Regeneron Healthcare Solutions, Inc. | 59 | $1,651 |
| CSL Behring | 38 | $1,108 |
| GSK | 50 | $1,026 |
| Novartis | 71 | $978 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $675 |
| Optinose US, Inc. | 28 | $642 |
| Sanofi | 24 | $604 |
| Grifols USA, LLC | 42 | $590 |
| Pfizer | 24 | $459 |
| Genentech USA, Inc. | 13 | $396 |
| Alk-abello, Inc | 23 | $333 |
| Octapharma USA, Inc. | 4 | $248 |
| Kaleo, Inc. | 13 | $244 |
| Amgen(2 entities) | 10 | $240 |
| Boehringer Ingelheim | 14 | $225 |
| Pharming Healthcare, Inc. | 11 | $211 |
| Biocryst US Sales Co., LLC | 8 | $173 |
| Sanofi-aventis U.S. LLC | 2 | $124 |
| Lilly USA, LLC | 2 | $56 |
| Merck | 3 | $53 |
| Incyte Corporation | 2 | $53 |
| Biocompatibles, Inc. | 1 | $50 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Blueprint Medicines Corporation | 2 | $42 |
| Eyevance Pharmaceuticals LLC | 2 | $41 |
| Medtronic | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Boston Scientific | 1 | $24 |
| GC Biopharma USA, Inc. | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,054 in reported general payments places this provider in the 90th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 11 | $452,974 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 129 | $91,467 |
| Spiriva RespimatTiotropium Bromide | 41 | $21,970 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $19,387 |
| Arnuity ElliptaFluticasone Furoate | 32 | $10,038 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $7,026 |
| XhanceFluticasone Propionate | 13 | $6,516 |
| Epinephrine | 31 | $6,090 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,764 |
| Qvar RedihalerBeclomethasone Dipropionate | 26 | $5,249 |
| Ipratropium Bromide | 131 | $4,771 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 32 | $4,332 |
| Azelastine Hcl | 124 | $3,547 |
| Fluticasone Propionate | 198 | $3,061 |
| Olopatadine Hcl | 39 | $2,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $173 | $452,97411 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,026 | $120,892210 claims |
| Boehringer IngelheimSpiriva Respimat | $225 | $21,97041 claims |
| Optinose US, Inc.Xhance | $642 | $6,51613 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $6,09031 claims |
| AstraZenecaSymbicort | $12,609 | $5,76416 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $47 | $5,24926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 allergy providers in Florida.
Other allergy in Orange Park
- Miguel LanzCoral Gables$778K
- Brett StanalandNaples$575K
- David RoseEglin Afb$253K
- Pavana BeerelliRockledge$61K
- Hugh WindomSarasota$37K
- Mark MinorMelbourne$21K
- Alan KoterbaNorth Palm Beach$16K
- Brian WilsonTallahassee$11K
- Sanjay SwamiJacksonville$11K
- Latha ChamarthyPinellas Park$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.